4
Changes in Ownership
VERTEX PHARMACEUTICALS INC / MA Filed Acc 0001209191-23-007827
EVP, Global Research and CSO sold 1,304 shares at an average $306.00 ($399,022)
- EVP, Global Research and CSO acquired 1,304 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
ALTSHULER DAVID · EVP, Global Research and CSO
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-02-06 | Exercise or conversion : show line 1 in the form | +1,304 | $187.53 | $244,539 | 69,949 | D |
| 2023-02-06 | Sale : show line 2 in the form | −12 | $300.39 | $3,605 | 69,937 | D |
| 2023-02-06 | Sale : show line 3 in the form | −70 | $302.00 | $21,140 | 69,867 | D |
| 2023-02-06 | Sale : show line 4 in the form | −100 | $303.64 | $30,364 | 69,767 | D |
| 2023-02-06 | Sale : show line 5 in the form | −349 | $305.08 | $106,473 | 69,418 | D |
| 2023-02-06 | Sale : show line 6 in the form | −620 | $306.70 | $190,154 | 68,798 | D |
| 2023-02-06 | Sale : show line 7 in the form | −153 | $309.06 | $47,286 | 68,645 | D |
| Open-market sales · 1,304 sh · avg $306.00 · $399,022 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2023-02-06 | Exercise or conversion : show line 8 in the form Stock Option (Right to Buy) | −1,304 | $187.53 | 2029-02-05 | 1,304 | 0 | D |
Loading xslF345X03/doc4.xml…